Adriamycin in hyperthermic perfusion for advanced limb sarcomas

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• High-grade soft tissue sarcomas pose significant treatment challenges.
• Limb-sparing surgery is a critical goal in managing extremity sarcomas.
• Adriamycin is a chemotherapeutic agent used in sarcoma treatment.

Purpose of the Study:

• To evaluate the efficacy and toxicity of hyperthermic limb perfusion (HLP) with adriamycin (ADR) for high-grade soft tissue sarcomas.
• To assess tumor necrosis rates and the feasibility of limb-sparing surgery following HLP-ADR.

Main Methods:

• 12 patients with high-grade soft tissue sarcomas underwent HLP with ADR.
• ADR was administered at a mean temperature of 41.5°C for 60 minutes.
• Tumor necrosis was evaluated radiologically, and locoregional toxicity was graded.

Main Results:

• Significant tumor necrosis was observed in 8 out of 12 patients (50%-75% in five, >75% in three).
• Limb-sparing surgery was feasible in 10 patients.
• No systemic toxicity was reported; locoregional toxicity ranged from grade II to IV.

Conclusions:

• HLP with ADR is a viable treatment option for high-grade soft tissue sarcomas, inducing substantial tumor necrosis.
• This approach facilitates limb-sparing surgery and shows manageable locoregional toxicity.
• Further research may explore optimizing HLP-ADR protocols for improved outcomes.